VEMERIX's Report Highlights Global Transition to Endovenous Laser Ablation from Traditional Surgery

Shift to Endovenous Laser Ablation

VEMERIX recently unveiled a comprehensive industry report detailing the significant transition from open vein surgery to minimally invasive endovenous laser ablation (EVLA) for treating varicose veins. The findings provide a deep exploration of how the landscape is changing, elucidating consumer preferences, technological advancements, and market dynamics over the coming years.

A Deep Dive into the Report

Titled From Stripping to Light: The Global Shift to Endovenous Ablation for Varicose Veins, the report analyzes a range of data sources, including US Medicare statistics, FDA databases, and patent filings. According to VEMERIX’s findings, the share of open vein surgeries under US Medicare service has plummeted from 10.3% in 2013 to 4.5% in 2024. This shift translates to a staggering 45% reduction in services provided and a 66% decrease in Medicare expenditure. Notably, traditional vein-stripping procedures have been nearly phased out.

The overall market for varicose vein treatment devices is currently valued at approximately USD 1.4 to 1.6 billion, projected to grow at a compound annual growth rate (CAGR) of between 5.5% to 9.0% through early 2030s. The EVLA segment continues to be the most rapidly expanding, exhibiting a growth rate of 7.4% to 7.9%.
North America holds a significant share, accounting for 46% to 48% of the market, while Asia-Pacific emerges as the fastest-growing region with a remarkable CAGR of up to 8.4%. This regional growth offers promising opportunities for manufacturers focused on exports.

Understanding the Value Dynamics

One of the primary revelations of the report is the assertion that the true value in the EVLA space lies not in the costly laser systems, but rather in the consumable single-use devices. This shift mirrors a